CcNav: Understanding Compiler Optimizations in Binary Code

Devkota, Sabin; Aschwanden, Pascal; Kunen, Adam; Legendre, Matthew; Isaacs, Katherine E.

doi:10.1109/tvcg.2020.3030357

Cited by 17 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostate cancer (14,15), colorectal cancer (16), hepatocellular carcinoma (17), and nonsmall cell lung carcinoma (18) have all been linked to miR154 (18). Nonsmall cell lung cancer (19), gastric carcinoma (20), ovarian cancer (21), colorectal cancer (22)(23), bladder cancer (24), breast cancer (25), and esophageal carcinoma (26) have all been linked to miR429 expression (26). Breast cancer (27-29), gastric cancer (30, 31), bladder cancer (32), lung adenocarcinoma (33), liver cancer (34), prostate cancer (35), and hepatocellular carcinoma (36), have all been linked to miR485 in some way (36, 37).…”

Section: Discussionmentioning

confidence: 99%

In diffuse intrinsic pontine gliomas, non-coding RNA expression is significantly varied dependent on overall survival

Castillo¹,

Mellor²,

Marks³

et al. 2021

Preprint

View full text Add to dashboard Cite

Diffuse intrinsic pontine glioma is a kind of pediatric brain cancer that kills 99 percent of patients within five years and for which there are no conventional chemotherapies. It is crucial for new treatments to comprehend the cancer's transcriptional activity. Using a published dataset, we compared the transcriptomes of tumors from patients who lived longer or less than six months. Among the genes whose expression changed most, we observed that numerous microRNAs and snoRNAs were present. The publication's findings are the first evidence of variable levels of non-coding RNA expression in diffuse intrinsic pontine glioma.

show abstract

Section: Discussionmentioning

confidence: 99%

In diffuse intrinsic pontine gliomas, non-coding RNA expression is significantly varied dependent on overall survival

Castillo¹,

Mellor²,

Marks³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Gastric cancer, gliomas and glioblastomas, squamous cell carcinomas of the tongue, pancreatic cancer, renal carcinoma, gallbladder cancer, and colorectal cancer are only a few examples (11)(12)(13)(14)(15)(16)(17)(18)(19). Three independent investigations concluded that elevated ZFX expression is protumorigenic and/or promotes tumor development in breast cancer (20)(21)(22). According to one of these investigations, suppressing ZFX resulted in a reduction in breast cancer cell growth (20).…”

Section: Discussionmentioning

confidence: 99%

“…According to one of these investigations, suppressing ZFX resulted in a reduction in breast cancer cell growth (20). Another investigation discovered a connection between increased ZFX expression and metastatic progression (21). A third research discovered that the long non-coding RNA was critical for triple negative breast cancer cells through ZFX suppression by microRNA 218.…”

Section: Discussionmentioning

confidence: 99%

ZFX expression is connected with improved survival in patients with breast cancer

Carney¹,

Bush²,

Sellers³

et al. 2021

Preprint

View full text Add to dashboard Cite

We analyzed published tumor transcriptome data in conjunction with linked survival data to identify genes linked with breast cancer survival outcomes (1, 2). When comparing tumor transcriptomes based on 24-month survival, we discovered that the zinc-finger protein X-linked ZFX (3, 4) was among the most differentially expressed genes in both original and metastatic tumor tissues. ZFX expression was considerably enhanced in metastatic tumors of patients who survived more than 24 months, indicating that enhanced ZFX expression offers a survival advantage for patients with stage IV metastatic breast cancer.

show abstract

“…Although the addition of erlotinib to gemcitabine resulted in a statistically significant improvement, the median PFS was just one-third of a month (12). The addition of cisplatin (22) or oxaliplatin (21) to gemcitabine, as well as the addition of bevacizumab (14), did not enhance median PFS, although the addition of capecitabine demonstrated a small increase in median PFS from 4.3 months to 3.9 months in the gemcitabine alone group (19). Identification of unique vulnerabilities in PDAC and subsequent development of tailored therapeutics are critical.…”

Section: Introductionmentioning

confidence: 91%

“…Increased toxicity is associated with both FOLFIRINOX and the addition of nab-paclitaxel (15,16). As adjuvants to gemcitabine, pemetrexed (17), erlotinib (18), a tyrosine kinase inhibitor, capecitabine (19), bevacizumab (20), and platinum drugs like oxaliplatin (21) have all been explored. Although the addition of erlotinib to gemcitabine resulted in a statistically significant improvement, the median PFS was just one-third of a month (12).…”

Section: Introductionmentioning

confidence: 99%

In pancreatic ductal adenocarcinoma, differential expression of the methyltransferases METTL1, METTL6, and METTL10 is linked to a worse overall survival rate

Paul¹,

Weston²,

Morin³

et al. 2021

Preprint

View full text Add to dashboard Cite

PDAC (pancreatic ductal adenocarcinoma) is one of the worst malignancies in men. We used a public datasetof resected tumors from 79 individuals with PDAC to undertake global differential gene expression analysis(1). We discovered that methyltransferase-like 6 and methyltransferase-like 10, METTL6 and METTL10, wereamong the most differentially expressed genes transcriptome-wide and that their expression was significantlyassociated with poorer survival when we compared the transcriptomes of these tumors based on overallsurvival greater or less than 1 year from diagnosis. METTL6 is a tRNA methyltransferase that is involved inthe m3c RNA modification (2), whereas METTL10 is a lysine methyltransferase that is involved in theeukaryotic translation factor EF1A1 (3). When patients with PDAC were categorized based on survival, asimilar enzyme, METTL1 (5, 6), was similarly differently expressed, according to a separate dataset (4). Theseresults suggest that METTL1, METTL6, and METTL10 might be used as therapeutic targets in a disease withno known targeted medicines, a median survival of 6 months, and a 5-year survival rate of 3-5 percent (7).

show abstract

CcNav: Understanding Compiler Optimizations in Binary Code

Cited by 17 publications

References 30 publications

In diffuse intrinsic pontine gliomas, non-coding RNA expression is significantly varied dependent on overall survival

In diffuse intrinsic pontine gliomas, non-coding RNA expression is significantly varied dependent on overall survival

ZFX expression is connected with improved survival in patients with breast cancer

In pancreatic ductal adenocarcinoma, differential expression of the methyltransferases METTL1, METTL6, and METTL10 is linked to a worse overall survival rate

Contact Info

Product

Resources

About